The global pandemic is creating some unexpected and innovative partnerships in healthcare. Some say this could be the beginning of a much-needed reset on many issues in the industry – especially drug pricing.
Can we take advantage of this disruption to spur new thinking about the value of medicines across the United States, Europe, and emerging countries?
Join industry experts as they discuss whether we will see a break from the status quo or a return to business as usual once the pandemic is over. Kate Dion, Value Communications Lead at 3D Communications, will serve as moderator for this webinar with:
- Indranil Bagchi, Senior Vice President and Head of Global Value and Access, Novartis Oncology
- Valentino Confalone, General Manager, Gilead Sciences, Italy
- Edmund Pezalla, Former Aetna Executive and Founder of Enlightenment Bio Consult
- Michael Schroeter, Founder of Swiss Investment Firm, VIOPAS
Indranil Bagchi, Senior Vice President and Head of Global Value and Access, Novartis Oncology
Indranil Bagchi drives the overall strategy on value demonstration, market access, and stakeholder engagement through appropriate pricing strategies, health economic modelling, outcomes research, real world evidence and innovative mechanisms that increase access to our cancer medicines. Bagchi has more than two decades of experience in Pricing & Reimbursement, Health Economics & Outcomes Research, and Market Access across several major companies in the pharmaceutical industry.
In 2014, he received the “Outstanding 50 Asian Americans in Business” award by the Asian American Business Development Center. In 2010, Bagchi was recognized in Pharmaceutical Executive magazine’s annual roster of Emerging Leaders, “The New Breed of Leadership.” Due to his efforts in securing and expanding market access for Enbrel in rheumatoid arthritis and psoriasis, he was awarded the Wyeth President’s Achieving Excellence Award in 2005. He is a frequent speaker and contributor to forums, articles, and conferences addressing issues related to access to medicines.
Valentino Confalone, General Manager, Gilead Sciences, Italy
Valentino Confalone works closely with a wide range of stakeholders in the healthcare system to address market access issues. He has negotiated numerous deals with Italian authorities who have implemented innovative payment models.
As Chairman of the Advance Therapy Medical Products group of the Italian trade association Farmindustria, Confalone is working with the Italian authorities on the development of a Value Framework for advanced therapies.
Before coming to Gilead, he was Head of Europe Dompé Biotech and at Bristol Myers Squibb (BMS). At BMS, Confalone worked on both the national and international level, including as Oncology Market Access Lead Europe. There, he developed the access and pricing strategies for the first immuno-oncology treatment, ipilimumab, for the treatment of advanced melanoma.
Confalone started his career in the pharma industry with Schering-Plough in Spain.
Edmund Pezalla, Founder and CEO, Enlightenment Bioconsult LLC
Edmund Pezalla, MD, MPH, is a strategic payer consultant, who advises biopharmaceutical firms on access, technology assessment, and drug evaluation in the United States. He was Vice President for Pharmaceutical Policy and Strategy for Aetna, and Vice President of Clinical Services for RxSolutions. In these roles, Pezalla developed programs for drug and device evaluation, created clinical policy and formulary inclusion. He also served as the leading executive for Aetna on public policy issues related to drug approval, drug pricing, and regulation.
Pezalla is a member of the MIT Center for Biomedical Innovation NEWDIGS project and was a member of the inaugural class of Scholars-in-Residence at the Duke-Margolis Center for Health Policy.
Michael Schroeter, Founding Partner, Viopas Partners AG
Michael Schroeter co-leads portfolio management and oversees sustainable healthcare investment strategy at Viopas, a Swiss investment firm. Viopas is one of the first asset managers to invest exclusively in healthcare companies that offer cost-effective solutions as well as improved clinical outcomes.
Prior to joining Viopas, Schroeter worked in the Global Access department at F. Hoffmann-La Roche, where he was responsible for establishing sustainable innovative pricing models in 20 major markets. Schroeter, who holds a PhD in biochemistry and immunology, set-up and led research and translational medicine units at both Roche and Eli Lilly. He has served on the boards of several start-up biotech and medical technology companies.
Kate Dion, Executive Communications Coach, 3D Communications
As an executive communications coach with a specialty in value communications, Kate works closely with executives to cut through the noise and focus on smart communications strategies that maximize the impact of their narratives.
Before joining 3D, Kate had careers in both the pharmaceutical industry and as a Life Sciences reporter. Kate worked as a Reuters correspondent based in Zurich, where she covered the Swiss healthcare industry. She then moved to industry, working at F. Hoffmann-La Roche’s pharmaceutical division in Switzerland, where she held numerous positions in the Global and Regional Europe organizations, including the role of International Communications Lead for Pricing.
Who Should Attend?
This webinar will benefit pharmaceutical executives including C-suite, market access, communications, and medical affairs professionals, healthcare investment firms, policymakers and payers.
What You Will Learn
In this webinar, you will learn about:
- Practical obstacles preventing change;
- The latest thinking on how a growing group of influential stakeholders can collaborate to improve outcomes for patients, payers, and the healthcare system overall; and
- The changes we need to make to ensure affordable and sustainable delivery of innovation after the pandemic.
3D Communications is the global leader in preparing Pharmaceutical, Biotech, and Medical Device companies for FDA and EMA regulatory meetings, including FDA Advisory Committee meetings and CHMP/SAG/Oral Explanations. We also specialize in preparing teams for launch and value communications, including market access negotiations. 3D’s team of 65 full-time colleagues specializes in all aspects of both virtual and live meeting preparation. Our team’s experience from hundreds of regulatory and commercial projects, our proven 3D ACT® process, and our state-of-the-art technology ensure our clients are prepared for the best possible outcome in the most challenging situations.